Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Gene Editing: The Regulatory Perspective

Version 1 : Received: 28 July 2023 / Approved: 28 July 2023 / Online: 31 July 2023 (04:55:07 CEST)

How to cite: Niazi, S.K. Gene Editing: The Regulatory Perspective. Preprints 2023, 2023072062. https://doi.org/10.20944/preprints202307.2062.v1 Niazi, S.K. Gene Editing: The Regulatory Perspective. Preprints 2023, 2023072062. https://doi.org/10.20944/preprints202307.2062.v1

Abstract

Gene or genome editing (GE) revises, removes, or replaces a mutated gene at the DNA level; it is a tool. Gene therapy (GT) offsets mutations by introducing a "normal" version of the gene into the body while the diseased gene remains in the genome; it is a medicine. So far, no GE product has been approved, as opposed to 22 GT products that cost up to millions of dollars per dose. The FDA has recently added a guideline specific to gene editing that should be understood to enable faster development of GE products; at the same time, the FDA also needs to bring more clarification and make several amendments to this guideline to make it more rational.

Keywords

gene editing; gene therapy; FDA; regulatory approval

Subject

Medicine and Pharmacology, Clinical Medicine

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.